CN100467454C - 取代的螺苯并氮杂 - Google Patents

取代的螺苯并氮杂 Download PDF

Info

Publication number
CN100467454C
CN100467454C CNB2004800231176A CN200480023117A CN100467454C CN 100467454 C CN100467454 C CN 100467454C CN B2004800231176 A CNB2004800231176 A CN B2004800231176A CN 200480023117 A CN200480023117 A CN 200480023117A CN 100467454 C CN100467454 C CN 100467454C
Authority
CN
China
Prior art keywords
compound
compounds
chloro
disease
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800231176A
Other languages
English (en)
Chinese (zh)
Other versions
CN1835925A (zh
Inventor
M·帕特尔
P·J·赖布钦斯基
M·A·香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1835925A publication Critical patent/CN1835925A/zh
Application granted granted Critical
Publication of CN100467454C publication Critical patent/CN100467454C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2004800231176A 2003-06-17 2004-06-16 取代的螺苯并氮杂 Expired - Fee Related CN100467454C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
US60/479,378 2003-06-17

Publications (2)

Publication Number Publication Date
CN1835925A CN1835925A (zh) 2006-09-20
CN100467454C true CN100467454C (zh) 2009-03-11

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800231176A Expired - Fee Related CN100467454C (zh) 2003-06-17 2004-06-16 取代的螺苯并氮杂

Country Status (30)

Country Link
US (2) US20040266752A1 (enExample)
EP (1) EP1633719B1 (enExample)
JP (1) JP5252614B2 (enExample)
KR (1) KR101086246B1 (enExample)
CN (1) CN100467454C (enExample)
AR (1) AR044782A1 (enExample)
AT (1) ATE444953T1 (enExample)
AU (1) AU2004281257C1 (enExample)
BR (1) BRPI0411598A (enExample)
CA (1) CA2529649C (enExample)
CL (1) CL2004001507A1 (enExample)
CR (1) CR8168A (enExample)
CY (1) CY1109585T1 (enExample)
DE (1) DE602004023501D1 (enExample)
DK (1) DK1633719T3 (enExample)
EA (1) EA011089B1 (enExample)
ES (1) ES2332724T3 (enExample)
HR (2) HRP20051006A2 (enExample)
IL (1) IL172630A (enExample)
ME (1) ME00320B (enExample)
NO (1) NO20060247L (enExample)
NZ (1) NZ544180A (enExample)
PL (1) PL1633719T3 (enExample)
PT (1) PT1633719E (enExample)
RS (1) RS20050930A (enExample)
SI (1) SI1633719T1 (enExample)
TW (1) TWI354555B (enExample)
UA (1) UA82236C2 (enExample)
WO (1) WO2005037795A2 (enExample)
ZA (1) ZA200600430B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
ATE532786T1 (de) * 2006-09-22 2011-11-15 Janssen Pharmaceutica Nv Spirobenzazepine als vasopressinantagonisten
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
WO2009061786A2 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
RU2642783C2 (ru) 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение
US20240190884A1 (en) * 2021-03-05 2024-06-13 Shanghai Jemincare Pharmaceutical Co., Ltd New-type benzazepine fused ring derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106802A (zh) * 1993-07-29 1995-08-16 美国氰胺公司 三环苯并吖庚因(氮杂䓬)后叶加压素拮抗剂
WO1997049707A1 (en) * 1996-06-27 1997-12-31 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US20030045517A1 (en) * 2000-07-05 2003-03-06 Chen Robert H.K. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
DE69026708T2 (de) 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
EP0663827A4 (en) * 1992-10-07 1995-11-15 Merck & Co Inc TOKOLYTIC OXYTOCINE RECEPTOR ANTAGONISTS.
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ES2143049T3 (es) * 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106802A (zh) * 1993-07-29 1995-08-16 美国氰胺公司 三环苯并吖庚因(氮杂䓬)后叶加压素拮抗剂
WO1997049707A1 (en) * 1996-06-27 1997-12-31 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US20030045517A1 (en) * 2000-07-05 2003-03-06 Chen Robert H.K. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Also Published As

Publication number Publication date
AR044782A1 (es) 2005-10-05
AU2004281257C1 (en) 2010-07-01
MEP49108A (en) 2011-02-10
EP1633719A2 (en) 2006-03-15
SI1633719T1 (sl) 2010-01-29
CR8168A (es) 2008-09-10
KR101086246B1 (ko) 2011-11-23
CL2004001507A1 (es) 2005-05-27
EA011089B1 (ru) 2008-12-30
KR20060023157A (ko) 2006-03-13
HRP20090606T1 (hr) 2010-01-31
CA2529649A1 (en) 2005-04-28
PL1633719T3 (pl) 2010-03-31
IL172630A0 (en) 2006-04-10
BRPI0411598A (pt) 2006-08-29
DK1633719T3 (da) 2010-01-04
US20040266752A1 (en) 2004-12-30
ATE444953T1 (de) 2009-10-15
US20070179128A1 (en) 2007-08-02
AU2004281257A1 (en) 2005-04-28
WO2005037795A3 (en) 2005-07-28
HRP20051006A2 (en) 2006-05-31
JP2007521272A (ja) 2007-08-02
RS20050930A (sr) 2008-04-04
CA2529649C (en) 2012-01-31
ES2332724T3 (es) 2010-02-11
NO20060247L (no) 2006-03-13
DE602004023501D1 (de) 2009-11-19
EP1633719B1 (en) 2009-10-07
JP5252614B2 (ja) 2013-07-31
CY1109585T1 (el) 2014-08-13
ZA200600430B (en) 2009-08-26
US7687494B2 (en) 2010-03-30
PT1633719E (pt) 2009-11-11
ME00320B (me) 2011-05-10
AU2004281257B2 (en) 2010-02-04
WO2005037795A2 (en) 2005-04-28
IL172630A (en) 2011-10-31
EA200501831A1 (ru) 2006-06-30
CN1835925A (zh) 2006-09-20
UA82236C2 (en) 2008-03-25
NZ544180A (en) 2009-01-31
TWI354555B (en) 2011-12-21
TW200515911A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
US7687494B2 (en) Substituted spirobenzazepines
JP5362565B2 (ja) オピオイド受容体のアンタゴニストまたはインバースアゴニストである新規化合物
US7825111B2 (en) Substituted spiroheterocycles
JP2010500372A (ja) オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
ES2374582T3 (es) Espirobenzazepinas usadas como antagonistas de vasopresina.
ES2250432T3 (es) Espirobenzoazepinas no peptidicas sustituidas, antagonistas de la vasopresina.
CA2539566A1 (en) Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
Yuan et al. Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5
CN103073455B (zh) 一类新型的kcnq钾通道激动剂、其制备方法和用途
ES2277745A1 (es) Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
CA2104626A1 (en) Pharmaceutical compounds
MXPA05014057A (en) Substituted spirobenzazepines
JP3030091B2 (ja) ３−アミノ−ベンゾ［ｂ］アゼピノンを製造するための方法および中間体
CN100551915C (zh) 8-氯-2,3-苯二氮䓬衍生物
KR20060102554A (ko) 사람 ｏｒｌ1 수용체에 대한 효능제로서의 벤즈이미다졸론및 퀴나졸리논 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090311

Termination date: 20210616